「CYP3A4」に関連した動画の一覧

	01/05 - CYP3A4 - profesor Perlík  2010年12月24日再生回数 173
	CYP3A4-&-CYP2D6  composició per a guitarra 2012年02月05日再生回数 19
	New Colchicine Product and Dosing Regimen (October 2009)  FDA has approved the first single-ingredient oral colchicine product. The drug, called Colcrys, is approved to treat acute gout flares and familial Mediterranean fever. Oral colchicine has been used to treat gout in the past, but until now it had not been approved by FDA. Colchicine has historically been given every hour for acute gout flares, either until the flare subsided or treatment had to be stopped because the patient developed gastrointestinal problems. But a dosing study conducted as part of the approval of Colcrys demonstrated that one initial dose and a single additional dose after one hour was just as effective and much less toxic. Healthcare professionals should use this lower recommended dosing regimen to treat acute gout flares. Healthcare professionals should also be aware that colchicine interacts with other drugs, including P-glycoprotein and strong CYP3A4 inhibitors such as cyclosporine and clarithromycin. This can lead to serious or even fatal colchicine toxicity, particularly if a patient has renal or hepatic impairment. And so concomitant use of colchicine and P-glycoprotein or strong CYP3A4 inhibitors is contraindicated in these patients. For patients with normal renal and hepatic function, consider interrupting colchicine therapy or reducing the dose if the patient needs treatment with a P-glycoprotein or a strong CYP3A4 inhibitor. 2009年10月07日再生回数 5813
	New Colchicine Product and Dosing Regimen  FDA has approved the first single-ingredient oral colchicine product. The drug, called Colcrys, is approved to treat acute gout flares and familial Mediterranean fever. Oral colchicine has been used to treat gout in the past, but until now it had not been approved by FDA. Colchicine has historically been given every hour for acute gout flares, either until the flare subsided or treatment had to be stopped because the patient developed gastrointestinal problems. But a dosing study conducted as part of the approval of Colcrys demonstrated that one initial dose and a single additional dose after one hour was just as effective and much less toxic. Healthcare professionals should use this lower recommended dosing regimen to treat acute gout flares. Healthcare professionals should also be aware that colchicine interacts with other drugs, including P-glycoprotein and strong CYP3A4 inhibitors such as cyclosporine and clarithromycin. This can lead to serious or even fatal colchicine toxicity, particularly if a patient has renal or hepatic impairment. And so concomitant use of colchicine and P-glycoprotein or strong CYP3A4 inhibitors is contraindicated in these patients. For patients with normal renal and hepatic function, consider interrupting colchicine therapy or reducing the dose if the patient needs treatment with a P-glycoprotein or a strong CYP3A4 inhibitor. FDA Patient Safety News: October 2009 For more information, please see our website: www.accessdata.fda.gov 2009年10月23日再生回数 2103
	Trisorbagen - Amp Your Supplements Into Overdrive!  Did You Know.... ...Your body has many mechanisms built into place to limit the absorption, active duration, and overall potency of a compound? Mechanisms such as high acidic environments and numerous inhibitory enzymes. One inhibitory enzyme, the the CYP3A4 enzyme, is present right now in your body and has probably limited some of the supplements you've already taken today. CYP3A4 specifically is considered to be a major drug metabolizing enzyme, and it is believed that inhibition of this enzyme could result in less of an ingredient needing to be used to achieve maximum concentrations in the blood stream. Hmmm, think about that for a moment. Taking fewer servings/day for an equal effect? Or, think of it this way! Same daily serving size, higher concentrations of the supplement in your blood stream, and magnified muscle building, strength enhancing results???! Now we're talking! Afterall, can you imagine what would happen if Mass FX, Hard FX, Lean FX were made even MORE effective? Introducing Trisorbagen! www.athleticxtreme.com 2010年09月16日再生回数 650
	Drug대사 pathway  항응고제로 혈액 응고를 방지하기 위한 약물로 알려진 쿠마딘의 대사에 대한 pathway 2010年10月21日再生回数 76
	exitalopramming.e la chitarra urlante.  escitalopram molecola Escitalopram Nome IUPAC (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Identificatori Numero CAS 128196-01-0 Codice ATC N06AB10 PubChem 146570 DrugBank APRD00683 Caratteristiche generali Formula C20H21FN2O MM 324.392 g/mol SMILES N#Cc1ccc2c(COC2(CCCN(C)C)c2ccc(F)cc2)c1 Dati farmacologici Categoria farmacoterapeutica ? Teratogenicità ? Fascia farmacologica ? Regime di dispensazione al pubblico ? Modalità di somministrazione ? Dati farmacocinetici Biodisponibilità 80% Metabolismo Epatico, grazie agli enzimi CYP3A4 e CYP2C19 Emivita 27-32 ore Escrezione ? L'Escitalopram (commercializzato come Cipralex o Entact) è un antidepressivo appartenente alla classe degli SSRI (dall'inglese "selective serotonin reuptake inhibitor", inibitore selettivo della ricaptazione della serotonina). È usato per il trattamento della depressione e il disturbo d'ansia generalizzato; è usato anche per il trattamento della Fobia sociale, attacchi di panico e il disturbo ossessivo compulsivo. L'Escitalopram è l'Enantiomero del precedente farmaco di Lundbeck citalopram (Celexa), da qui il nome escitalopram (che si legge es-citalopram). L'Escitalopram è conosciuto per la sua alta selettività dell'inibizione della ricaptazione della serotonina e come risultato il farmaco ha meno effetti collaterali non legati alla sua attività serotoninergica [1]. Secondo le analisi di 12 antidepressivi di nuova generazione, l'escitalopram e la sertralina ... 2011年05月05日再生回数 169
	Il sole può influenzare l'efficacia dei farmaci nel corpo  Uno studio del Karolinska Institutet ha mostrato che vi è un rapporto tra decadimento, e quindi efficacia dei farmaci, ed esposizione alla luce del sole. Vi è quindi un rapporto con le stagioni. 2011年05月10日再生回数 22
	FDA Drug Info Rounds, May 2010: Single-ingredient Oral Colchicine  Although unapproved colchicine has been used for many years, FDA approved the first single-ingredient oral colchicine product, Colcrys, in July 2009 for the treatment of familial Mediterranean fever (FMF) and acute gout flares; in October 2009 Colcrys was approved for prophylaxis of gout flares (chronic gout). The approved prescribing information for Colcrys includes a new drug interaction warning, updated dosing recommendations and a medication guide. Pharmacists are reminded to dispense only FDA approved products. FDA Drug Info Rounds pharmacists discuss the differences between approved and unapproved colchicine products, concerns regarding unapproved single-ingredient oral colchicine, and how patients can offset the increased cost of Colcrys. For more information, please see our website: www.fda.gov 2010年05月21日再生回数 6032
	Inner Workings of Cytochrome P450 2C9  This animation shows an 'inside view' of the workings of the enzyme cytochrome P-450 2C9. The protein, represented by the ribbon and yellow spheres, is from an x-ray crystal structure of a drug metabolizing enzyme called cytochrome P-450 2C9. The larger of the two ligands (clusters of spheres) is the heme group, which acts as cofactor to assist in the catalytic reaction. The smaller of the two ligands is the drug warfarin (an anticoagulant) which is the substrate for the catalytic reaction. First both ligands are bound. Then the warfarin molecule moves from solution (outside the protein) and finds a channel by which to access its specific binding site. The warfarin molecule finds its way through the channel to find its preferred binding position near the active site. This model will now be used to illustrate how different drugs interact with this enzyme, and thus interfere with optimum warfarin therapy, a common clinical problem. Created by: Steven Barbera - Business/CommunicationsSteven Barbera Class of 2007 Business/Communications STA member since 2003 Dr. King - Biomedical and Pharmaceutical SciencesDr. Roberta King Assistant Professor of Biomedical and Pharmaceutical Sciences College of Pharmacy 2007年05月02日再生回数 14401